Literature DB >> 28337374

Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM.

Junyi Jiang1, Xu Chen2, Hao Liu2, Jing Shao3, Ruihui Xie2, Peng Gu2, Chaohui Duan1.   

Abstract

Polypyrimidine Tract-Binding Protein 1 (PTBP1) is an essential RNA-binding protein that regulates diverse biological events through regulating alternative splice of mRNA. PTBP1 induces cancer-promoting splice variants and is related to tumorigenesis in several cancers. However, both the expression patterns and biological mechanisms of PTBP1 in clear-cell renal cell carcinoma (ccRCC) are unclear. We investigated PTBP1 expression in 533 ccRCC patients from TCGA and 30 ccRCC patients by immunohistochemistry, and found that PTBP1 expression levels were significantly increased in ccRCC tissues and that high PTBP1 expression was closely correlated with advanced tumor stage, AJCC stage and poor prognosis. Cell biological assays with siRNA-mediated knockdown and lentivirus vector-mediated over-expression demonstrated that PTBP1 promoted proliferation, migration and invasion in ccRCC cells in vitro. Furthermore, PTBP1 increased the transformation from pyruvate kinase muscle 1 (PKM1) to PKM2. Knockdown of PKM2 mainly abolished PTBP1-induced proliferation, migration and invasion in ccRCC cells in vitro. In conclusion, our study indicates that PTBP1 plays a tumorigenic role in ccRCC by mediating PKM2 alternative splicing and it may be a potential prognostic marker and a promising target for treatment of ccRCC.

Entities:  

Keywords:  PKM2; PTBP1; metastasis; proliferation; renal cell carcinoma

Year:  2017        PMID: 28337374      PMCID: PMC5336499     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  52 in total

Review 1.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

2.  Molecular-targeted Therapy and Surgery May Prolong Survival of Renal Cell Carcinoma Patients with Bone Metastasis: A Multi-institutional Retrospective Study in Japan.

Authors:  Hiroshi Kitamura; Atsushi Takahashi; Fumiyasu Takei; Hiroshi Hotta; Noriomi Miyao; Tetsuya Shindo; Manabu Igarashi; Hitoshi Tachiki; Yasuharu Kunishima; Takashi Muranaka; Masanori Shigyo; Yoshinori Ikehata; Naoya Masumori
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

3.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes.

Authors:  B Altenberg; K O Greulich
Journal:  Genomics       Date:  2004-12       Impact factor: 5.736

4.  Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function.

Authors:  Xu Chen; Jueheng Wu; Hanning Liu; Zhenjian He; Minghui Gu; Ning Wang; Jianda Ma; Jieping Hu; Lei Xia; Haipeng He; Jie Yuan; Jun Li; Luyuan Li; Mengfeng Li; Xun Zhu
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

5.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.

Authors:  Wei-Ren Liu; Meng-Xin Tian; Liu-Xiao Yang; Yu-Li Lin; Lei Jin; Zhen-Bin Ding; Ying-Hao Shen; Yuan-Fei Peng; Dong-Mei Gao; Jian Zhou; Shuang-Jian Qiu; Zhi Dai; Rui He; Jia Fan; Ying-Hong Shi
Journal:  Oncotarget       Date:  2015-01-20

8.  Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer.

Authors:  Xu Chen; Peng Gu; Ruihui Xie; Jinli Han; Hao Liu; Bo Wang; Weibin Xie; Weijie Xie; Guangzheng Zhong; Changhao Chen; Shujie Xie; Ning Jiang; Tianxin Lin; Jian Huang
Journal:  J Cell Mol Med       Date:  2016-11-10       Impact factor: 5.310

9.  PTBP1 and PTBP2 impaired autoregulation of SRSF3 in cancer cells.

Authors:  Jihua Guo; Jun Jia; Rong Jia
Journal:  Sci Rep       Date:  2015-09-29       Impact factor: 4.379

10.  MiR-133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle-splicer polypyrimidine tract-binding protein 1.

Authors:  Taro Sugiyama; Kohei Taniguchi; Nobuhisa Matsuhashi; Toshihiro Tajirika; Manabu Futamura; Tomoaki Takai; Yukihiro Akao; Kazuhiro Yoshida
Journal:  Cancer Sci       Date:  2016-12-19       Impact factor: 6.716

View more
  15 in total

1.  lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.

Authors:  Peng Gu; Xu Chen; Ruihui Xie; Jinli Han; Weibin Xie; Bo Wang; Wen Dong; Changhao Chen; Meihua Yang; Junyi Jiang; Ziyue Chen; Jian Huang; Tianxin Lin
Journal:  Mol Ther       Date:  2017-05-06       Impact factor: 11.454

2.  The renaissance man of burn surgery: Basil A. Pruitt, Jr.

Authors:  Karel D Capek; Guillermo Foncerrada; R Patrick Clayton; Michaela Sljivich; Charles D Voigt; Gabriel Hundeshagen; Janos Cambiaso-Daniel; Craig Porter; Ashley Guillory; David N Herndon
Journal:  J Trauma Acute Care Surg       Date:  2017-11       Impact factor: 3.313

3.  Radix Rehmannia Glutinosa inhibits the development of renal fibrosis by regulating miR-122-5p/PKM axis.

Authors:  Xinhua Liu; Honglan Xu; Yunhua Zang; Weiguo Liu; Xiangbo Sun
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 4.  Roles of PTBP1 in alternative splicing, glycolysis, and oncogensis.

Authors:  Wei Zhu; Bo-Lun Zhou; Li-Juan Rong; Li Ye; Hong-Juan Xu; Yao Zhou; Xue-Jun Yan; Wei-Dong Liu; Bin Zhu; Lei Wang; Xing-Jun Jiang; Cai-Ping Ren
Journal:  J Zhejiang Univ Sci B       Date:  2020-02-05       Impact factor: 3.066

5.  DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.

Authors:  Ziyue Chen; Xu Chen; Ruihui Xie; Ming Huang; Wen Dong; Jinli Han; Jingtong Zhang; Qianghua Zhou; Hui Li; Jian Huang; Tianxin Lin
Journal:  Mol Ther       Date:  2019-01-09       Impact factor: 11.454

Review 6.  The Krebs Cycle Connection: Reciprocal Influence Between Alternative Splicing Programs and Cell Metabolism.

Authors:  Giuseppe Biamonti; Lucia Maita; Alessandra Montecucco
Journal:  Front Oncol       Date:  2018-09-26       Impact factor: 6.244

7.  A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.

Authors:  Peng Gu; Xu Chen; Ruihui Xie; Weibin Xie; Li Huang; Wen Dong; Jinli Han; Xiaodong Liu; Jihong Shen; Jian Huang; Tianxin Lin
Journal:  Mol Cancer       Date:  2019-06-20       Impact factor: 27.401

8.  Survival-Associated Alternative Splicing Events in Pan-Renal Cell Carcinoma.

Authors:  Keren Jia; Yingcheng Wu; Jing Huang; Huiqun Wu
Journal:  Front Oncol       Date:  2019-11-27       Impact factor: 6.244

9.  LncRNA HOTTIP facilitates cell proliferation, invasion, and migration in osteosarcoma by interaction with PTBP1 to promote KHSRP level.

Authors:  Xin-Yu Yao; Jian-Fan Liu; Yi Luo; Xue-Zheng Xu; Jie Bu
Journal:  Cell Cycle       Date:  2021-01-21       Impact factor: 4.534

10.  Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.

Authors:  Jingtong Zhang; Qianghua Zhou; Keji Xie; Liang Cheng; Shengmeng Peng; Ruihui Xie; Lixuan Liu; Yangjie Zhang; Wen Dong; Jinli Han; Ming Huang; Yuelong Chen; Tianxin Lin; Jian Huang; Xu Chen
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.